What does this research mean for the field?

Elranatamab monotherapy is highly active and demonstrates a favorable safety profile as an early intervention for high-risk smoldering multiple myeloma, achieving a 92% overall response rate. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the safety and efficacy of elranatamab in patients with high-risk smoldering multiple myeloma.

May 29, 2026Journal of Clinical Oncology

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

View Full Paper

Ask AI

Bookmark

Authors

CTCyrille TouzeauCentre Hospitalier Universitaire de Nantes FSFredrik SchjesvoldOslo University Hospital CCClaudio CerchioneIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Discussion

Member takes

Implication

Randomized trial reports high efficacy and safety of Elranatamab in high-risk smoldering myeloma, suggesting it as a new treatment option.

Key Points

The aim is to evaluate the safety and efficacy of elranatamab in patients with high-risk smoldering multiple myeloma.
Phase 2 open-label multicenter trial in high-risk smoldering multiple myeloma patients.
Patients received single-agent subcutaneous elranatamab for 2 years following a fixed dosing schedule.
Primary endpoint focused on the complete response rate, with safety as a key secondary endpoint.
Overall response rate was 92% with 45% achieving complete response or better.
Cytokine release syndrome occurred in 68% of patients, mostly grade 1-2.
9-month progression-free survival rate was 95% and overall survival rate was 100%.

Cite This Study

Touzeau et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417fb7 https://doi.org/10.1200/jco.2026.44.16_suppl.7500

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reports high efficacy and safety of Elranatamab in high-risk smoldering myeloma, suggesting it as a new treatment option.

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider